Cutia Therapeutics (HK:2487)
:2487
Top Page
Cutia Therapeutics
(2487)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$4.50
▼(-1.96% Downside)
Action:ReiteratedDate:11/22/25
Cutia Therapeutics faces significant challenges with profitability and cash flow, which heavily impact its financial performance score. The technical analysis indicates bearish momentum, and valuation metrics are unfavorable due to negative earnings. These factors collectively result in a low overall stock score.
Positive Factors
Revenue Growth
Sustained revenue growth near 26% demonstrates improving commercial traction and product uptake. Over a 2–6 month horizon this supports reinvestment in R&D and operations, reduces execution risk, and increases the odds management can scale toward durable profitability if growth persists.
Negative Factors
Negative Cash Flow
Persistent negative operating and free cash flow constrains internal funding for trials and commercialization, forcing ongoing reliance on external capital. Over several months this raises dilution or interest costs, limits strategic optionality, and can delay development milestones if financing is tight.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue growth near 26% demonstrates improving commercial traction and product uptake. Over a 2–6 month horizon this supports reinvestment in R&D and operations, reduces execution risk, and increases the odds management can scale toward durable profitability if growth persists.
Read all positive factors
Cutia Therapeutics (2487) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.69B
Dividend YieldN/A
Average Volume (3M)399.60K
Price to Earnings (P/E)―
Beta (1Y)1.00
Revenue Growth25.89%
EPS Growth12.90%
CountryHK
Employees333
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.30
Shares Outstanding364,730,870
10 Day Avg. Volume272,590
30 Day Avg. Volume399,603
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.00
Price to Sales (P/S)6.98
P/FCF Ratio-4.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$7.45Price Target Upside62.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.76
Revenue Forecast (FY)HK$588.00M
Cutia Therapeutics Business Overview & Revenue Model
Company Description
Cutia Therapeutics operates as a biopharmaceutical company that develops a dermatology platform for skin and scalp diseases. The company focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation mana...
How the Company Makes Money
Cutia Therapeutics generates revenue primarily through the sale of its pharmaceutical products, which are marketed to healthcare providers and institutions. The company also engages in strategic partnerships with other biotech firms and pharmaceut...
Cutia Therapeutics Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 250.33M | 279.62M | 137.62M | 11.37M | 2.04M |
| Gross Profit | 125.19M | 143.46M | 71.01M | 7.94M | 1.61M |
| EBITDA | -422.82M | -430.69M | -1.92B | -535.19M | -309.23M |
| Net Income | -472.27M | -433.81M | -1.96B | -555.84M | -319.58M |
Balance Sheet | |||||
| Total Assets | 1.12B | 1.39B | 1.71B | 1.45B | 1.49B |
| Cash, Cash Equivalents and Short-Term Investments | 681.51M | 876.15M | 1.27B | 1.08B | 1.38B |
| Total Debt | 290.40M | 320.94M | 243.75M | 54.13M | 26.53M |
| Total Liabilities | 359.62M | 418.51M | 357.76M | 2.69B | 2.29B |
| Stockholders Equity | 756.62M | 974.73M | 1.35B | -1.25B | -790.51M |
Cash Flow | |||||
| Free Cash Flow | -209.64M | -468.66M | -437.23M | -371.50M | -185.76M |
| Operating Cash Flow | -196.82M | -442.98M | -381.31M | -236.19M | -159.88M |
| Investing Cash Flow | 272.88M | 316.07M | -203.58M | 462.06M | -410.65M |
| Financing Cash Flow | 32.50M | 37.84M | 588.32M | -10.25M | 480.76M |
Cutia Therapeutics Technical Analysis
Negative
4.59
Price Trends
4.80
Negative
5.27
Negative
7.25
Negative
Market Momentum
-0.06
Positive
45.63
Neutral
40.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2487, the sentiment is Negative. The current price of 4.59 is below the 20-day moving average (MA) of 4.78, below the 50-day MA of 4.80, and below the 200-day MA of 7.25, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 45.63 is Neutral, neither overbought nor oversold. The STOCH value of 40.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2487.
Cutia Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | HK$4.17B | 7.02 | 4.48% | ― | -8.11% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$2.42B | -14.44 | -27.70% | ― | -100.00% | 30.68% | |
44 Neutral | HK$1.96B | -3.21 | -137.11% | ― | ― | -18.99% | |
42 Neutral | HK$13.59B | -15.44 | -64.19% | ― | -55.64% | -158.67% | |
41 Neutral | HK$1.69B | -4.07 | -41.22% | ― | 25.89% | 12.90% | |
37 Underperform | HK$5.67B | -31.16 | -17.64% | ― | 770.20% | 87.27% |
* Healthcare Sector Average
HK:2487
Cutia Therapeutics
4.63
0.35
8.18%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
7.20
4.56
172.73%
HK:1873
Viva Biotech Holdings
1.97
0.76
62.81%
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
4.10
-2.71
-39.79%
HK:2616
CStone Pharmaceuticals
9.35
7.13
321.17%
HK:3681
SinoMab Bioscience Ltd.
1.76
0.58
49.15%
Cutia Therapeutics Corporate Events
Cutia Therapeutics’ Botulinum Toxin CU-20101 Meets Phase III Goals in China
Jan 19, 2026
Cutia Therapeutics announced that its investigational product CU-20101, a botulinum toxin type A injection for treating moderate to severe glabellar lines, has delivered positive topline results in a Phase III clinical trial in China. In a randomi...
Cutia Therapeutics Reshapes Board with Resignation of Dr. Huang and Appointment of Veteran Executive Lu Minfang
Dec 30, 2025
Cutia Therapeutics announced that non-executive director Dr. Huang Xiao will resign from the board with effect from 30 December 2025 to focus on personal commitments, with both the company and Dr. Huang confirming there are no disagreements or iss...
Cutia Therapeutics Updates Board and Committee Structure
Dec 30, 2025
Cutia Therapeutics has announced the latest composition of its board of directors, comprising executive directors Zhang Lele and Huang Yuqing, several non-executive directors, and three independent non-executive directors. The company has also det...
Cutia Therapeutics’ Topical Finasteride Spray Gains Regulatory Acceptance
Nov 18, 2025
Cutia Therapeutics has announced that their Abbreviated New Drug Application for CU-40105, a self-developed topical finasteride spray for treating androgenetic alopecia, has been accepted by China’s National Medical Products Administration. ...
Cutia Therapeutics’ Acne Treatment Shows Promising Early Results
Nov 10, 2025
Cutia Therapeutics announced that a post-hoc analysis of their Phase III clinical trial for CU-10201, a topical 4% minocycline foam, has been accepted for presentation at the 20th CDA Annual Meeting. The analysis revealed that CU-10201 demonstrate...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.